Barclays
HRTX icon

Barclays’s Heron Therapeutics HRTX Stock Holding History

Barclays’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.1K Sell
91,394
-211,815
-70% -$245K ﹤0.01% 4162
2025
Q4 		$394K Buy
303,209
+23,852
+9% +$29.4K ﹤0.01% 3976
2025
Q3 		$352K Sell
279,357
-42,067
-13% -$66.7K ﹤0.01% 3999
2025
Q2 		$665K Buy
321,424
+138,878
+76% +$284K ﹤0.01% 3593
2025
Q1 		$402K Sell
182,546
-58,800
-24% -$114K ﹤0.01% 3654
2024
Q4 		$369K Buy
241,346
+22,891
+10% +$37.1K ﹤0.01% 4003
2024
Q3 		$435K Buy
218,455
+50,109
+30% +$120K ﹤0.01% 3863
2024
Q2 		$589K Buy
168,346
+31,887
+23% +$98K ﹤0.01% 2944
2024
Q1 		$378K Sell
136,459
-42,295
-24% -$106K ﹤0.01% 3765
2023
Q4 		$304K Buy
178,754
+124,044
+227% +$137K ﹤0.01% 4194
2023
Q3 		$56.4K Sell
54,710
-2,523
-4% -$3.59K ﹤0.01% 3822
2023
Q2 		$66.4K Sell
57,233
-41,700
-42% -$74.4K ﹤0.01% 3717
2023
Q1 		$149K Buy
98,933
+24,314
+33% +$60.9K ﹤0.01% 3959
2022
Q4 		$187K Sell
74,619
-351,735
-82% -$1.13M ﹤0.01% 3879
2022
Q3 		$1.8M Buy
426,354
+288,093
+208% +$1.13M ﹤0.01% 1823
2022
Q2 		$385K Sell
138,261
-1,050
-0.8% -$4.22K ﹤0.01% 3045
2022
Q1 		$797K Sell
139,311
-2,553
-2% -$18.7K ﹤0.01% 2569
2021
Q4 		$1.29M Buy
141,864
+55,786
+65% +$570K ﹤0.01% 2661
2021
Q3 		$921K Buy
86,078
+43,159
+101% +$525K ﹤0.01% 2839
2021
Q2 		$666K Sell
42,919
-95,707
-69% -$1.52M ﹤0.01% 2904
2021
Q1 		$2.25M Buy
138,626
+70,775
+104% +$1.26M ﹤0.01% 2179
2020
Q4 		$1.44M Sell
67,851
-3,485
-5% -$60.6K ﹤0.01% 2506
2020
Q3 		$1.06M Buy
71,336
+2,542
+4% +$39.7K ﹤0.01% 2641
2020
Q2 		$1.01M Buy
68,794
+25,337
+58% +$416K ﹤0.01% 2746
2020
Q1 		$511K Sell
43,457
-44,813
-51% -$842K ﹤0.01% 3567
2019
Q4 		$2.07M Sell
88,270
-6,184
-7% -$137K ﹤0.01% 2960
2019
Q3 		$1.75M Buy
94,454
+44,722
+90% +$823K ﹤0.01% 3033
2019
Q2 		$924K Buy
49,732
+11,053
+29% +$221K ﹤0.01% 3757
2019
Q1 		$945K Buy
38,679
+12,686
+49% +$332K ﹤0.01% 3460
2018
Q4 		$674K Sell
25,993
-35,566
-58% -$978K ﹤0.01% 3524
2018
Q3 		$1.95M Buy
61,559
+53,320
+647% +$1.99M ﹤0.01% 2911
2018
Q2 		$320K Sell
8,239
-22,159
-73% -$705K ﹤0.01% 4329
2018
Q1 		$839K Buy
30,398
+18,792
+162% +$426K ﹤0.01% 3424
2017
Q4 		$210K Sell
11,606
-17,185
-60% -$280K ﹤0.01% 4654
2017
Q3 		$465K Buy
28,791
+23,426
+437% +$367K ﹤0.01% 3701
2017
Q2 		$74K Buy
5,365
+3,456
+181% +$50.1K ﹤0.01% 5114
2017
Q1 		$29K Sell
1,909
-10,429
-85% -$144K ﹤0.01% 5621
2016
Q4 		$162K Buy
12,338
+11,715
+1,880% +$184K ﹤0.01% 4387
2016
Q3 		$10K Sell
623
-30,282
-98% -$562K ﹤0.01% 5791
2016
Q2 		$558K Buy
30,905
+22,199
+255% +$433K ﹤0.01% 3121
2016
Q1 		$157K Buy
8,706
+3,818
+78% +$75.3K ﹤0.01% 4021
2015
Q4 		$127K Buy
4,888
+4,520
+1,228% +$121K ﹤0.01% 4247
2015
Q3 		$9K Sell
368
-153
-29% -$5.1K ﹤0.01% 5818
2015
Q2 		$17K Sell
521
-183
-26% -$3.44K ﹤0.01% 5779
2015
Q1 		$11K Sell
704
-1,188
-63% -$13.4K ﹤0.01% 6177
2014
Q4 		$19K Buy
1,892
+1,127
+147% +$9.2K ﹤0.01% 6347
2014
Q3 		$6K Sell
765
-160
-17% -$1.49K ﹤0.01% 7106
2014
Q2 		$11K Buy
+925
New +$11.1K ﹤0.01% 6782

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.29B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return